Macrophage inflammatory protein-2 (MIP-2)

Macrophage inflammatory protein-2 (MIP-2, also termed CXCL2) is a small secreted chemokine belonging to the CXC family; it is produced by macrophages, monocytes, epithelial cells, hepatocytes, and other cell types in response to infection or tissue injury[1][2][3]. MIP-2 binds to CXCR1 and CXCR2 receptors, leading to potent recruitment and activation of neutrophils, thus playing a critical role in the acute innate immune response and inflammation. It exerts its effects through MAPK and NF-κB–dependent signaling pathways, and its expression can be upregulated in conditions like liver injury, sepsis, and certain pulmonary and central nervous system diseases[1][4]. In addition, MIP-2 is implicated in disease progression and tissue damage via excessive neutrophil activity, but at lower concentrations, it supports tissue regeneration, notably in the liver. Dysregulated MIP-2 signaling contributes to the pathology of several inflammatory and infectious disease states, and it is under investigation as a biomarker and potential therapeutic target, though clinical translation has not yet been achieved[1][4][2].

Other names

Chemokine (C-X-C motif) ligand 2CXCL2Macrophage inflammatory protein 2MIP-2MIP2

Neutralization of MIP-2 (antibody-based inhibition), blocking neutrophil chemotaxis and activation; inhibition of MIP-2 expression by targeting transcriptional pathways (e.g., NF-κB inhibitors, antioxidants such as N-acetylcysteine); modulation via upstream immune pathways (e.g., TLR4 inhibition).